fluoxetine has been researched along with Raynaud Disease in 9 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Raynaud Disease: An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Khouri, C | 1 |
| Gailland, T | 1 |
| Lepelley, M | 1 |
| Roustit, M | 1 |
| Cracowski, JL | 1 |
| de Vries-Bouwstra, JK | 1 |
| Allanore, Y | 2 |
| Matucci-Cerinic, M | 2 |
| Balbir-Gurman, A | 1 |
| Kowal-Bielecka, O | 1 |
| Fransen, J | 1 |
| Avouac, J | 1 |
| Becker, M | 1 |
| Kulak, A | 1 |
| Distler, O | 1 |
| Clements, P | 1 |
| Cutolo, M | 1 |
| Czirjak, L | 1 |
| Damjanov, N | 1 |
| Del Galdo, F | 1 |
| Denton, CP | 2 |
| Distler, JHW | 1 |
| Foeldvari, I | 1 |
| Figelstone, K | 1 |
| Frerix, M | 1 |
| Furst, DE | 1 |
| Guiducci, S | 1 |
| Hunzelmann, N | 1 |
| Khanna, D | 1 |
| Herrick, AL | 1 |
| van den Hoogen, F | 1 |
| van Laar, JM | 1 |
| Riemekasten, G | 1 |
| Silver, R | 1 |
| Smith, V | 1 |
| Sulli, A | 1 |
| Tarner, I | 1 |
| Tyndall, A | 1 |
| Welling, J | 1 |
| Wigley, F | 1 |
| Valentini, G | 1 |
| Walker, UA | 1 |
| Zulian, F | 1 |
| Müller-Ladner, U | 1 |
| Korkmaz, S | 1 |
| Işik, U | 1 |
| Korkmaz, H | 1 |
| Jaffe, IA | 1 |
| Bolte, MA | 1 |
| Avery, D | 1 |
| Rudnick, A | 1 |
| Modai, I | 1 |
| Zelikovski, A | 1 |
| De Broucker, T | 1 |
| Lhote, F | 1 |
| Coleiro, B | 1 |
| Marshall, SE | 1 |
| Howell, K | 1 |
| Blann, A | 1 |
| Welsh, KI | 1 |
| Black, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aiming to Reduce Disease-related Gastrointestinal Symptoms in Systemic Sclerosis by Repeat Intestinal Infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Randomized, Double-blind Placebo-controlled 20 Week Study[NCT04300426] | Phase 2 | 75 participants (Actual) | Interventional | 2020-09-24 | Completed | ||
| "Effect of a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis on Oxygen Consumption, Functionality, and Quality of Life"[NCT06105073] | 67 participants (Anticipated) | Observational [Patient Registry] | 2022-03-01 | Recruiting | |||
| A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon[NCT00351117] | Phase 3 | 20 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Potential Benefit for Non Invasive Vagus Nerve Stimulation (nVNS) Using GammaCore in the Treatment of Raynaud's Phenomena.[NCT03869008] | 7 participants (Actual) | Interventional | 2019-04-30 | Terminated (stopped due to Funding no longer available) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluoxetine and Raynaud Disease
| Article | Year |
|---|---|
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
1 trial available for fluoxetine and Raynaud Disease
| Article | Year |
|---|---|
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Topics: Adult; Aged; Cold Temperature; Cross-Over Studies; Female; Fluoxetine; Humans; Male; Middle Aged; Ni | 2001 |
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Topics: Adult; Aged; Cold Temperature; Cross-Over Studies; Female; Fluoxetine; Humans; Male; Middle Aged; Ni | 2001 |
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Topics: Adult; Aged; Cold Temperature; Cross-Over Studies; Female; Fluoxetine; Humans; Male; Middle Aged; Ni | 2001 |
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Topics: Adult; Aged; Cold Temperature; Cross-Over Studies; Female; Fluoxetine; Humans; Male; Middle Aged; Ni | 2001 |
7 other studies available for fluoxetine and Raynaud Disease
| Article | Year |
|---|---|
Fluoxetine and Raynaud's phenomenon: friend or foe?
Topics: Fluoxetine; Humans; Raynaud Disease; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2017 |
Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis.
Topics: Adrenal Cortex Hormones; Angiotensin-Converting Enzyme Inhibitors; Europe; Fluoxetine; Gastroesophag | 2020 |
Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.
Topics: Amlodipine; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Clonaze | 2011 |
Serotonin reuptake inhibitors in Raynaud's phenomenon.
Topics: 1-Naphthylamine; Adult; Aged; Cyclohexanols; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxeti | 1995 |
Case of fluoxetine-induced remission of Raynaud's phenomenon--a case report.
Topics: Adult; Female; Fluoxetine; Humans; Raynaud Disease; Remission Induction | 1993 |
Fluoxetine-induced Raynaud's phenomenon.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Female; Fluoxetine; Humans; Middle Aged; | 1997 |
[Severe Raynaud's phenomenon associated with interferon-beta 1a and fluoxetine].
Topics: Adjuvants, Immunologic; Adult; Anticoagulants; Antidepressive Agents, Second-Generation; Depressive | 2000 |